Literature DB >> 28407303

Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension.

Elena-Mihaela Cordeanu1, Sébastien Gaertner1, Alix Faller1, Corina Mirea1, Jean-Marc Lessinger2, Veronique Kemmel2, Dominique Stephan1,3.   

Abstract

Dihydropyridine calcium-channel blockers are a known substrate for the cytochrome P450 isoform 3A4. Rifampicin, an antitubercular agent, is one of the most potent inducers of hepatic and intestinal CYP3A4 thus increasing dihydropyridine metabolism. We report a case of a 67-year-old hypertensive female treated with a four-drug antihypertensive regimen including a dihydropyridine (nicardipine 50 mg bid), who was admitted for septic arthritis of the knee requiring antibiotic treatment with teicoplanin 400 mg od and rifampicin 600 mg bid. Six days after rifampicin initiation, she presented with Posterior Reversible Encephalopathy Syndrome due to uncontrolled hypertension. We hypothesized that disequilibrium of previously controlled hypertension was partially due to nicardipine ineffectiveness. Plasma nicardipine concentration was assessed through high-performance liquid chromatography 5 hours after coadministration of the two drugs and proved undetectable.
© 2017 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  CYP3A4; arterial hypertension; dihydropyridine; hepatic inducer; rifampicin

Mesh:

Substances:

Year:  2017        PMID: 28407303     DOI: 10.1111/fcp.12292

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

1.  Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine.

Authors:  Yu Eun Sunwoo; Phuong Thi Thu Nguyen; Chin May Chien; Ji Young Ryu; Jihong Shon; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2019-01-30       Impact factor: 4.335

2.  Abnormal Dexamethasone Suppression Tests in a Rifapentine-Treated Patient With Primary Aldosteronism.

Authors:  Hongman Wang; Ying Song; Zhixin Xu; Ying Jing; Wenwen He; Zhengping Feng; Qifu Li; Shumin Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-04       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.